For the Inventor, By the Inventor

Enter inventor name

Rehovot, Israel

Igor Mett

USPTO Granted Patents = 44 (Patent Applications = 19)

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 4.5

ph-index = 10

Forward Citations = 357(Granted Patents)

Company Filing History:

Quark Pharmaceuticals, Inc.

14 out of 1,168

Yeda Research and Develpment & Co. Ltd

Nitto-denko Corporation

4. 2 out of 1,586

Washington University

5. 1 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2020

Loading Chart...

Loading Chart...

Loading Chart...

Areas of Expertise:

Double-Stranded Oligonucleotides

p53 Targeting

Fibrosis Treatment

Retinoid-Lipid Drug Carrier

HSP47 Modulation

Lung Disease Therapy

siRNA Compounds

RTP801 Inhibitors

TNF Receptor Modulators

Eye Disorder Treatments

Regulatory Proteins Modulation

Stroke Response Genes

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10781449 - Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof (2020-09-22),

2. 10421962 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2019-09-24),

3. 10196637 - Retinoid-lipid drug carrier (2019-02-05),

4. 10195145 - Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier (2019-02-05),

5. 10093923 - Modulation of HSP47 expression (2018-10-09),

6. 9932578 - Double-stranded oligonucleotide molecules to P53 and methods of use thereof (2018-04-03),

7. 9822362 - Compositions and methods for treating lung disease and injury (2017-11-21),

8. 9796979 - Oligonucleotide modulators of the toll-like receptor pathway (2017-10-24),

9. 9701961 - Methods for treating eye disorders (2017-07-11),

10. 9611474 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2017-04-04),

11. 9487778 - Oligonucleotide modulators of the toll-like receptor pathway (2016-11-08),

12. 9456984 - Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier (2016-10-04),

13. 9222087 - Therapeutic uses of inhibitors of RTP801L (2015-12-29),

14. 9206424 - Modulation of HSP47 expression (2015-12-08),

15. 9205100 - Compositions and methods for treating lung disease and injury (2015-12-08),

Title: Inventor Igor Mett - Revolutionizing Technology in Rehovot

Introduction: Igor Mett is a visionary inventor based in Rehovot, Israel, known for his groundbreaking contributions to the field of technology.

Latest Patents: Igor Mett holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Igor Mett has worked with leading research institutions and tech companies, consistently pushing the boundaries of what is possible in the world of innovation.

Collaborations: Throughout his career, Igor Mett has collaborated with top scientists, engineers, and researchers globally, fostering a culture of innovation and excellence in all his projects.

Conclusion: Igor Mett's relentless pursuit of innovation and his passion for creating technology that makes a difference continue to inspire the next generation of inventors and entrepreneurs.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…